HIV prevention study for men who travel for work
Part of Infections clinical trials.
This study tests different ways to take HIV prevention medicine (PrEP) for men who travel for work. It compares daily pills, pills taken only around sex, and a long-acting injection to see which works best for mobile men in sub-Saharan Africa.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You were born male
- You have traveled for work or to find work and stayed away from home at least one night in the past 6 months
- You are willing to take an HIV test and learn the results
- You are available for follow-up visits for the entire study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study offers a new injectable medication called lenacapavir to prevent HIV. It is for people who are HIV-negative and sexually active, and want to try a long-acting injection instead of daily pills.
This study is for cis-gender men who are HIV-negative and at risk for HIV. It tests a program to help you start and stay on PrEP (medication to prevent HIV).
This study tests a new approach to help men at risk for HIV stay healthy by providing access to PrEP through a mobile app. The goal is to see if the program helps men start and stay on PrEP compared to standard care.
This study offers three ways to prevent HIV: a shot every two months (injectable PrEP), daily pills, or a vaginal ring. Researchers in Cape Town will help you choose the option that fits your life best.
This study tests a long-acting HIV prevention shot (Cabotegravir) or a vaginal ring (DapiRing) along with sexual health services for young people. It aims to find the best way to prevent HIV and support overall health.
This study follows adults who are at high risk of getting HIV while they take HIV prevention pills (PrEP). It aims to learn how well PrEP fits real-life use in people at risk and who may need extra care.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.